Abstracts tagged "Janus kinase (JAK) and drug interactions"

Abstract Number: 1459 • 2017 ACR/ARHP Annual Meeting
Lack of Drug-Drug Interaction between Filgotinib, a JAK-1 Selective Inhibitor, and a Representative Hormonal Contraceptive Medication, Levonorgestrel/Ethinyl Estradiol
Rebecca Begley¹, Kacey Anderson², Timothy R. Watkins¹, Jing Shen¹, Hao Zheng¹, Eugene Vass¹, Ann Qin², Brian P. Kearney² and Yan Xin², ¹Gilead Sciences, Inc., Foster City, CA, ²Clinical Pharmacology, Gilead Sciences, Inc., Foster City, CA
Background/Purpose: Filgotinib is a potent and selective JAK1 inhibitor in clinical development for treatment of inflammatory diseases, including rheumatoid arthritis and inflammatory bowel diseases. Filgotinib…
Abstract Number: 1481 • 2014 ACR/ARHP Annual Meeting
Phase 1 and Phase 2 Data Confirm That GLPG0634, a Selective JAK1 Inhibitor, Has a Low Potential for Drug-Drug Interactions
Namour Florence¹, Desrivot Julie¹, Annegret Van der Aa², Chantal Tasset³ and Gerben van 't Klooster², ¹Galapagos, Romainville, France, ²Galapagos NV, Mechelen, Belgium, ³Generaal de Wittelaan L11 A3, Galapagos NV, Mechelen, Belgium
Background/Purpose: GLPG0634 is an orally-available, selective Janus kinase 1 (JAK1) inhibitor. Selective inhibition of JAK1 may combine improved safety and clinical efficacy profiles with a rapid onset of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].